Name: Selank TP-7 Spray | 40mg | 30ml | Captide Labs
SKU: CPT-SPRY-Selank-40MG
Price: 109.99 USD
Availability: InStock

Description

Cognitive →·Performance →

Selank TP-7 Research Spray | Anxiolytic Tuftsin Analogue & Nootropic Heptapeptide

Captide Labs Selank TP-7 Spray delivers research-grade Selank in a pre-formulated, ready-to-use liquid spray format. Each 30ml bottle contains 40mg of Selank at greater than 98% purity, independently verified by HPLC-MS analysis and documented with a full Certificate of Analysis. Concentration is 1.33mg/ml, with each actuation delivering approximately 200–500mcg depending on application protocol.

Selank (CAS 129954-34-3, also designated TP-7) is a synthetic heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg) — an endogenous immunomodulatory tetrapeptide derived from the Fc region of immunoglobulin G. Selank extends the tuftsin core with a Pro-Gly-Pro C-terminal motif that shields it from aminopeptidase degradation and improves blood-brain-barrier permeability. Developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences under Nikolai F. Myasoedov, Selank is approved in Russia as a prescription 0.15% nasal spray for generalized anxiety disorder and neurasthenia — making it one of the few research peptides to have achieved full regulatory approval for a neurological indication. Russian clinical trials reported anxiolytic efficacy comparable to the benzodiazepine medazepam, without the sedation, tolerance, or dependence profile associated with that drug class.

Research Specifications

Compound

Selank (TP-7)

CAS Number

129954-34-3

Molecular Formula

C₃₃H₅₇N₁₁O₉

Molecular Weight

751.88 g/mol

Peptide Length

7 amino acids (heptapeptide)

Synonyms

TP-7, SEL-729, TKPRPGP

Purity

>98% (HPLC-MS Verified)

Amino Acid Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)

Format

Liquid Spray

Concentration

1.33mg/ml

Bottle Volume

30ml

Total Peptide Content

40mg

Spray Delivery

200–500mcg per actuation

Testing Standard

ISO 17025 Accredited Lab

Storage

Refrigerate at 2–8°C. Do not freeze in liquid form. Use within 28–30 days of opening.

What is Selank?

Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed as a stabilized analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the heavy chain of immunoglobulin G, known primarily for its immunomodulatory effects on macrophages and neutrophils. Tuftsin on its own has a plasma half-life measured in seconds because aminopeptidases cleave it rapidly. The Pro-Gly-Pro C-terminal extension added in Selank’s design dramatically slows that degradation and also improves blood-brain-barrier permeability — which is why the compound is delivered intranasally rather than orally in research and clinical applications.

Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences under Nikolai F. Myasoedov, Selank is approved in Russia as a prescription 0.15% nasal spray for anxiety disorders and neurasthenia — making it one of the few research peptides to have undergone full clinical development and obtained regulatory approval. Human clinical trials (Zozulya et al., 2008) demonstrated anxiolytic efficacy comparable to medazepam, without the sedation, tolerance, or dependence profile associated with the benzodiazepine class. Outside Russia and Eastern Europe, Selank is distributed as a research compound with a triple pharmacological profile spanning anxiolytic, nootropic, and immunomodulatory mechanisms.

Research Overview

Areas of Active Selank Investigation

GABAergic Modulation & Anxiolytic Signaling

Selank’s anxiolytic effects appear to be primarily mediated through GABAergic pathways. Studies have demonstrated that Selank influences GABA-A receptor function and modulates the expression of genes involved in GABAergic neurotransmission, producing benzodiazepine-comparable anxiolytic effects without sedation. A landmark 2008 clinical trial (Zozulya et al.) compared Selank directly to medazepam in patients with generalized anxiety disorder and neurasthenia, finding comparable anxiolytic efficacy with additional psychostimulant and antiasthenic properties in the Selank group — a profile not seen with benzodiazepines.

Enkephalinase Inhibition & Endogenous Opioid Tone

Selank potently inhibits enkephalinase enzymes — specifically the enzymes responsible for degrading endogenous enkephalins (small opioid-like neuropeptides involved in pain modulation, mood, and stress response). By slowing enkephalin breakdown, Selank enhances the body’s natural opioid-like signaling without directly binding opioid receptors. This mechanism is shared with Semax and is thought to contribute to both the anxiolytic and mood-regulating effects observed in preclinical models, while explaining the absence of tolerance and dependence typical of direct opioid receptor agonism.

BDNF Modulation & Neuroplasticity

Intranasal Selank has been shown to increase BDNF expression in the hippocampus in preclinical models, supporting neuroplasticity and potentially contributing to its sustained cognitive and anxiolytic effects. Researchers have examined Selank’s influence on the transcription of neurotrophins and their receptor genes in the context of stress models, with findings suggesting that BDNF upregulation may underlie the protective cognitive effects observed in studies on learning and memory in both normal and alcohol-impaired subjects.

Monoaminergic Neurotransmitter Research

Selank modulates the brain’s serotonergic, dopaminergic, and noradrenergic systems. Studies have documented increased serotonin turnover and potentiation of noradrenergic signaling following Selank administration. This broad monoaminergic activity profile makes it a useful research tool for investigating the interplay between these neurotransmitter systems in anxiety, mood regulation, motivation, and cognitive performance — and distinguishes it mechanistically from pure GABAergic anxiolytics.

Hippocampal Inhibitory Current Modulation

Cellular-level studies have characterized Selank’s effects on inhibitory postsynaptic currents (IPSCs) in the rat hippocampal CA1 region — a key brain area for memory formation and emotional regulation. At a concentration of 1 μM, Selank has been reported to increase both the amplitude and discharge rate of inhibitory postsynaptic currents in CA1 neurons. This electrophysiological signature is consistent with Selank’s behavioral anxiolytic profile and provides a mechanistic correlate for its observed effects in anxiety and stress models.

Immunomodulatory Research

As a tuftsin analogue, Selank retains and extends the immunomodulatory properties of its parent peptide. Preclinical studies have reported Selank-associated modulation of cytokine expression profiles — including effects on interleukin and interferon-related markers — making it a useful tool for investigating the intersection of peptide-mediated neuroimmune signaling and immune regulation. Researchers have also examined Selank in models of metabolic syndrome, where it has demonstrated effects on anticoagulation system functionality and fat accumulation markers.

Third-Party Certificate of Analysis

Every batch of Selank TP-7 Spray is independently tested by an ISO 17025-accredited laboratory. View the full COA including identity confirmation, purity assay, heavy metals, and microbial results on the Captide Labs Lab Reports page.

View COA →

Frequently Asked Questions

What is Selank used for in research?

Selank is used in preclinical and clinical research to study GABAergic anxiolytic signaling, enkephalinase inhibition, BDNF modulation, monoaminergic neurotransmitter systems, hippocampal inhibitory current regulation, and immunomodulatory mechanisms. It is approved as a prescription drug in Russia for anxiety and neurasthenia, giving it one of the more robust clinical evidence bases in the research peptide space. Researchers also investigate it in cognitive function models, stress response studies, and neuroimmune pathway research.

What is the concentration of this spray?

Each 30ml bottle contains 40mg of Selank, yielding a concentration of approximately 1.33mg/ml. Each actuation delivers 200–500mcg depending on the spray pump volume used. At 40mg total, this is a higher-load format than the 30mg sprays common in the market — providing more total peptide per bottle for extended or multi-dose research protocols.

How does Selank relate to tuftsin?

Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of immunoglobulin G, known primarily for its immunomodulatory effects on macrophages and neutrophils. Selank extends this sequence with a Pro-Gly-Pro C-terminal addition, which dramatically improves metabolic stability against enzymatic degradation — tuftsin has a plasma half-life measured in seconds due to aminopeptidase cleavage, whereas Selank is designed for sustained CNS activity. The modification also preserves and extends tuftsin’s neurotropic properties while enabling practical intranasal research delivery.

What is the CAS number for Selank?

The CAS number for Selank (TP-7) is 129954-34-3. It is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), molecular formula C₃₃H₅₇N₁₁O₉, and molecular weight 751.88 g/mol. It is also referenced under the designations TP-7, SEL-729, and Selanc — all reflecting its development as a tuftsin-derived research peptide at the Institute of Molecular Genetics of the Russian Academy of Sciences.

How does Selank differ from benzodiazepines in research models?

Benzodiazepines produce anxiolytic effects by directly binding and allosterically modulating GABA-A receptors, enhancing chloride ion conductance and producing CNS depression. This mechanism is associated with sedation, cognitive impairment, tolerance development, and dependence. Selank influences GABAergic neurotransmission through a distinct mechanism — modulating gene expression in GABAergic pathways rather than direct receptor binding — which preclinical and clinical research suggests produces anxiolytic effects without sedation, cognitive blunting, or dependency markers. This mechanistic distinction makes Selank a particularly useful research tool for studying anxiety pathway modulation without the confounding variables introduced by direct receptor agonism.

How should Selank TP-7 Spray be stored?

Store Selank TP-7 Spray refrigerated at 2–8°C. Do not freeze once in liquid form, as freeze-thaw cycling can compromise peptide integrity. Keep away from direct light and heat. Once opened, use within 28–30 days for best results. Note that the Russian pharmaceutical formulation of Selank includes a preservative that permits room-temperature stability — Captide Labs Selank Spray is a research-grade formulation and refrigeration is recommended at all times to maintain maximum potency.

For research use only. Not for human consumption, veterinary use, or food/agricultural applications. Not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. All purchases are made with the understanding that this compound is strictly for in-vitro research and laboratory use. See the full Research Use Only (RUO) Policy.

FDA Disclosure & Intended Use

FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.

Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.

Storage Instructions

Handling and Storage Tips:

Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.

Reviews (0)

Thanks for your review!

Your feedback helps us improve our service.

error

Please Insert Review Title

Please Insert Review Feedback

Please Insert Your Email

Yes

Research Use Only (RUO) Policy

"RUO" is an abbreviation for Research Use Only. It is a designation used primarily by the FDA (Food and Drug Administration) for products, often in vitro diagnostic (IVD) components like reagents or instruments, that are in the laboratory research phase of development and are not intended for clinical diagnostic use.

READ MORE